Piper Brian 4
4 · Prelude Therapeutics Inc · Filed Aug 27, 2021
Insider Transaction Report
Form 4
Piper Brian
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-25$1.89/sh+8,333$15,749→ 8,333 total - Sale
Common Stock
2021-08-25$32.44/sh−2,100$68,124→ 6,233 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-08-25−8,333→ 264,329 totalExercise: $1.89Exp: 2029-08-06→ Common Stock (8,333 underlying) - Sale
Common Stock
2021-08-25$33.23/sh−3,889$129,235→ 2,344 total - Sale
Common Stock
2021-08-25$34.33/sh−2,344$80,469→ 0 total
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.77 to $32.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.78 to $33.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.82 to $34.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]The stock option vested as to 25% of the total shares monthly beginning on July 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.